Hisamitsu Pharmaceutical Co Inc (FSE:4530) Stock Price, Trades & News

Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	49.95
Equity-to-Asset	0.8
Debt-to-Equity	0.01
Debt-to-EBITDA	0.08
Interest Coverage	853.24
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.74	Distress Grey Safe
Beneish M-Score	-2.21	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	12.2
	3-Year EBITDA Growth Rate	17.5
	3-Year EPS without NRI Growth Rate	22.7
	3-Year FCF Growth Rate	29.6
	3-Year Book Growth Rate	7.9
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	10.23
	Future 3-5Y Total Revenue Growth Rate Estimate	4.04

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	12-1 Month Momentum %	-5.69

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.08
	Quick Ratio	3.57
	Cash Ratio	2.35
	Days Inventory	135.33
	Days Sales Outstanding	111.5
	Days Payable	57.12

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Payout Ratio	0.17
	3-Year Dividend Growth Rate	-18.8
	3-Year Average Share Buyback Ratio	3.3
	Shareholder Yield %	-0.23

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	58.96
	Operating Margin %	10.99
	Net Margin %	11.75
	EBITDA Margin %	18.85
	FCF Margin %	5.78
	OCF Margin %	10.72
	ROE %	6.97
	ROA %	5.56
	ROIC %	7.03
	3-Year ROIIC %	9.31
	ROC (Joel Greenblatt) %	25.4
	ROCE %	8.01
	Years of Profitability over Past 10-Year	10
	Moat Score	6
	Tariff Resilience Score	5

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	14.8
	Forward PE Ratio	13.59
	PE Ratio without NRI	14.61
	Shiller PE Ratio	18.23
	PEG Ratio	0.72
	PS Ratio	1.76
	PB Ratio	0.96
	Price-to-Tangible-Book	0.98
	Price-to-Free-Cash-Flow	30.08
	Price-to-Operating-Cash-Flow	16.23
	EV-to-EBIT	13.17
	EV-to-EBITDA	10.15
	EV-to-Revenue	1.91
	EV-to-FCF	33.08
	Price-to-GF-Value	1.23
	Price-to-Projected-FCF	0.82
	Price-to-Median-PS-Value	0.59
	Price-to-Peter-Lynch-Fair-Value	0.63
	Price-to-Graham-Number	0.8
	Price-to-Net-Current-Asset-Value	2.14
	Price-to-Net-Cash	6.46
	Earnings Yield (Greenblatt) %	7.59
	FCF Yield %	2.22
	Forward Rate of Return (Yacktman) %	22.25

GF Value™: 円3237.07

FSE:4530

Warning Signs

Warning! GuruFocus detected 9 Good signs with 4530. Try a 7-Day Free Trial to check it out.

Hisamitsu Pharmaceutical Co Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Hisamitsu Pharmaceutical Co Inc Stock Events

Financials Calendars

Event	Date	Price (円)
0.0000000426:1 Stock Split	2026-05-11	3,975.00 (+0.00%)
JPY 15.000000 Cash Dividend	2025-08-28	3,975.00 (+0.00%)
JPY 45.000000 Cash Dividend	2025-08-28	3,975.00 (+0.00%)
JPY 2.000000 Cash Dividend	2025-02-27	4,215.00 (+0.00%)
JPY 43.000000 Cash Dividend	2025-02-27	4,215.00 (+0.00%)
JPY 2.000000 Cash Dividend	2024-08-29	4,215.00 (+0.00%)
JPY 43.000000 Cash Dividend	2024-08-29	4,215.00 (+0.00%)

Show

Entries

Press Release

	Subject	Date
No Press Release

Articles on Hisamitsu Pharmaceutical Co Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.